Cagrilintide

Status

No approved product. No FDA-approved labeling exists. Cagrilintide remains investigational.

What it is

A long-acting amylin analogue studied alongside GLP-1 agonists for appetite.

What published research measured

Phase 2 work has been published on cagrilintide alone and combined with semaglutide, reporting additive weight change. Independent replication is still limited.

Source

Garvey WT et al. 2025 — Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity · Frias JP et al. 2023 — Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2… · Enebo LB et al. 2021 — Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagri…

Sources

No linked primary source is on file for this entry yet.

Educational use only, never medical advice. No doses.